The U.S. Food and Drug Administration has approved an omega-3 fatty acid treatment as an add-on treatment to statin therapy to reduce the risk of cardiovascular disease in adults with elevated triglyceride levels.
MAASTRICHT, The Netherlands—Study results suggest that clinical trials of novel treatments targeting Lp(a) will not be affected by subjects with CV disease receiving antiplatelet therapy.
MAASTRICHT, The Netherlands--The significant combined effect of bempedoic acid and ezetimibe on LDL-C in patients at high risk for CV events may suggest a new era of non-statin therapy.
Test your knowledge of the key elements and outcomes of the highly buzzed about REDUCE-IT trial with this 5-question quiz.
How much do you know about the 2019 ACC/AHA guidelines on the primary prevention of cardiovascular disease? Take this 9-question quiz to find out.
Eighty percent of all cardiovascular events are preventable. The ACC/AHA 2019 guidelines are a single source of best practices to help achieve that goal. Review them here, at-a-glance.
In 2018, the American College of Cardiology and American Heart Association teamed up to update treatment guidelines for atherosclerotic cardiovascular disease. Learn more in this recap.
Results of an open label study on omega-3 PUFA supplementation found a small but transient effect on gut microbiota that could warrant future research.
Among lipid clinic patients, actual EPA+DHA supplement intake was <50% of prescribed dosage, according to the first study to look at the association.
Findings from REDUCE-IT are the first to show that EPA lowers the relative risk of hard cardiovascular endpoints. Johns Hopkins' Seth Martin, MD, and colleagues put the trial in perspective.